PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Coagulation Protein Disorders”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources
PubMed1965

Myelomatosis.

Explore the source record for details and available documents.

Blood Coagulation Disorders↗
PubMed1981

The effect of seromucoid on coagulation.

The purpose of this study was to investigate the effect on coagulation of alpha-acid-glycoprotein, one of the acute-phase reactants, the blood level of which is elevated in malignant disease and various acute conditions. Alpha-acid-glycoprotein was obtained from serum and plasma of normal volunteers. The amount obtainable from serum was greater than that obtained from plasma (43 mg/dl v. 22 mg/dl), and differences were noted in the molecular weight of the two preparations; alpha-acid-glycoprotein from serum had a molecular weight of 55 000, while that from plasma appeared to have a molecular weight of 81 000. The two preparations were identical in their reactivity towards anti-alpha-acid-glycoprotein. Alpha-acid-glycoprotein markedly shortened the partial thromboplastin time (PTT), but no effect on prothrombin index was noted. At those concentration which shortened the PTT, the preparation was able partially to reverse the anticoagulant activity of heparin. The possibility that this protein plays a role in the aetiology of coagulation disorders in cancer is discussed.

Blood Coagulation↗
PubMedDate not supplied

[Severe epistaxis in hemorrhagic syndromes (excepting Rendu-Osler disease)].

The existence of a general abnormality in haemostasis causes more copious and protracted haemorrhage but does not, in theory, cause epistaxis. Abnormalities in primary haemostasis are at the root of these serious haemorrhages (thrombocytopenia and Willebrand's disease). Haemophilia is more rarely the trigger for intractable epistaxis. Treatment consists of local measures and replacement therapy. In all cases local treatment should have as little traumatic effect as possible in order to avoid a recurrence of haemorrhage when compression is removed. In women with abnormal constitutional haemostasis, establishment of anovulatory cycles by means of oestro-progestatives prescribed to combat menorrhagia often lessens the seriousness of these epistaxes. Replacement therapy consists of platelet transfusions for thrombocytopenia, the introduction of Willebrand's factor for Willebrand's disease and antihaemophilic factors for haemophilia.

Adult↗
PubMed1996

Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease.

Since it has not been established to what extent abnormalities of hemostasis contribute to the occurrence and development of dementia, selected measurements of coagulation and fibrinolysis were obtained in elderly patients with Alzheimer's disease (n = 22) or vascular dementia (n = 29), compared with healthy individuals in the same age range (n = 61). Hemostasis abnormalities were more frequent and marked in vascular dementia, being expressed as significant increases of plasminogen activator inhibitor type 1, von Willebrand factor, D-dimer and activated factor VII. However, some hemostasis measurements (von Willebrand factor, activated factor VII) were abnormally high also in the patients with Alzheimer's disease, a condition in which vascular damage is not considered to play a major pathogenetic role. It could not be established in this study whether or not these hemostatic abnormalities play a casual role in the pathogenesis of dementia, or whether they are secondary to inflammation and chronic vascular disease. Nevertheless, their presence may contribute to aggravating vascular disease.

Aged↗